Page 78 | Certara

Blog

Dose Optimization Considerations for Targeted Radiation Therapies

The acquisitions of targeted radiation therapy companies (TRT) Point Biopharma by Eli Lilly and RayzeBio…

CertaraFebruary 16, 2024

Publication

The interaction of core modules as a basis for elucidating network behavior determining Parkinson’s disease pathogenesis

It is well-established that misfolded alpha-synuclein (alpha-syn) is a histopathological marker of Parkinson's disease. Given…

CertaraFebruary 14, 2024

On-Demand Webinar

Advancing Services & Software for INDs: How to Expedite IND Filing with a Subscription Model

When choosing how to accomplish your IND submission, there can be many elements to the…

CertaraFebruary 13, 2024

Conference

The 15th Japan Safety Pharmacology Society

CertaraFebruary 13, 2024

Brochure

ToxStudio®: Secondary Intelligence™ FAQs

CertaraFebruary 9, 2024

Video

D360 Scientific Informatics Discovery Platform: User Stories

Transcript: I've joined companies both blueprint medicines and score therapeutics is one of the first…

CertaraFebruary 8, 2024

Press Coverage

Upping the Ante for Predicting the Success of Alzheimer Disease Treatments

By Hugo Geerts, PhD, Piet van der Graaf, PharmD, PhD Over the past 20 years,…

CertaraFebruary 8, 2024

Conference

Clinical Data Disclosure, Transparency & Plain Language Summaries 2024

CertaraFebruary 7, 2024

Conference

DIA MASC

CertaraFebruary 2, 2024

On-Demand Webinar

Drug Development’s New Model: Biosimulation from Discovery to Label Expansion

Key Highlights: How predictive technologies reshape drug development, mitigating project risks, navigating novel biomarkers, predicting…

CertaraFebruary 2, 2024

Dose Optimization Considerations for Targeted Radiation Therapies

The interaction of core modules as a basis for elucidating network behavior determining Parkinson’s disease pathogenesis

Advancing Services & Software for INDs: How to Expedite IND Filing with a Subscription Model

The 15th Japan Safety Pharmacology Society

ToxStudio®: Secondary Intelligence™ FAQs

D360 Scientific Informatics Discovery Platform: User Stories

Upping the Ante for Predicting the Success of Alzheimer Disease Treatments

Clinical Data Disclosure, Transparency & Plain Language Summaries 2024

DIA MASC

Drug Development’s New Model: Biosimulation from Discovery to Label Expansion

Newsletter sign up

Quick links

Solutions

Contact